|
Mycobacterium leprae
(Immuno-prophylactic: all children in endemic areas. Immuno-therapeutic: all recently infected individuals)
|
Armadillo-derived M. leprae
|
88,481
|
271
|
|
Neisseria meningitidis
(Infants, 3–6 months)
|
Conjugated capsular polysaccharides, groups A,C,Y, and W135
|
13,754
|
708
|
|
Parainfluenza viruses
(Infants)
|
Trivalent, subunit vaccine (which must contain fusion proteins)
|
43,692
|
1,697
|
|
Plasmodium spp.
(All infants at risk, military personnel, travelers)
|
Plasmodium falciparum, synthetic or recombinant sporozoite antigen preparation
|
475,205
|
967
|
|
Multivalent synthetic or recombinant sporozoite antigen preparation (P. falciparum, P. vivax, P. ovale, P. malariae)
|
426,640
|
857
|
|
Rabies virus
(Individuals at high risk, plus post-exposure prophylaxis) (As above)
|
Vero cell
|
41,910
|
147
|
|
Glycoprotein produced by rDNA technology in mammalian cells
|
37,983
|
139
|
|
(Birth cohort in areas of high risk)
|
Attenuated live vector virus containing gene for protective glycoprotein antigen
|
8,260
|
16
|
|
Respiratory syncytial virus
(Infants)
|
Polypeptides produced by recombinant DNA technology
|
52,412
|
1,964
|
|
Attenuated live virus
|
59,559
|
983
|
